Highly Effective Oral Amphotericin B Formulation against Murine Visceral Leishmaniasis

Journal of Infectious Diseases

Volumn 200, Issue 3, 2009, Pages 357-360

  Wasan, Kishor M ^a   Wasan, Ellen K ^a,c   Gershkovich, Pavel ^a   Zhu, Xiaohua ^d   Tidwell, Richard R ^e   Werbovetz, Karl A ^d   Clement, John G ^b   Thornton, Sheila J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Ico Therapeutics   (Canada)

^c BRITISH COLUMBIA INSTITUTE OF TECHNOLOGY   (Canada)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; MILTEFOSINE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; PARASITEMIA; PHOSPHORYLCHOLINE;

EID: 67249146920     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/600105     Document Type: Article

References (15)

1. Singh RK, Pandey HP, Sundar S. Visceral leishmaniasis (kala-azar): challenges ahead. Indian J Med Res 2006; 123:331-44.
2. Sundar S, Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian J Med Res 2006; 123:345-52.
3. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5:873-82.
4. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dosefinding study. Trans R Soc Trop Med Hyg 1996; 90:319-22.
5. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005; 5: 763-74.
6. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996; 38:1041-7.
7. Le Fichoux Y, Rousseau D, Ferrua B, et al. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 1998; 42:654-8.
8. Berman JJ. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol 2008; 4:1209-16.
9. Thakur CP, Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 2004; 98: 129-38.
10. Golenser J, Domb A. New formulations and derivatives of amphotericin B for treatment of leishmaniasis. Mini Rev Med Chem 2006; 6: 153-62.
11. Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003; 254:73-5.
12. Delmas G, Park S, Chen ZW, et al. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 2002; 46:2704-7.
13. Zarif L, Graybill JR, Perlin D, Najvar L, Bocanegra R, Mannino RJ. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother 2000; 44:1463-9.
14. Escobar P, Yardley V, Croft S. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 2001; 45: 1872-1875.
15. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.